Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non-Current Assets (2016 - 2025)

Lineage Cell Therapeutics' Other Non-Current Assets history spans 16 years, with the latest figure at $558000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 9.12% year-over-year to $558000.0; the TTM value through Dec 2025 reached $558000.0, down 9.12%, while the annual FY2025 figure was $558000.0, 9.12% down from the prior year.
  • Other Non-Current Assets reached $558000.0 in Q4 2025 per LCTX's latest filing, up from $539000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $639000.0 in Q1 2022 to a low of $504000.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $584700.0, with a median of $597000.0 recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: rose 21.15% in 2021, then fell 17.38% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $630000.0 in 2021, then fell by 0.48% to $627000.0 in 2022, then dropped by 7.97% to $577000.0 in 2023, then increased by 6.41% to $614000.0 in 2024, then decreased by 9.12% to $558000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Other Non-Current Assets are $558000.0 (Q4 2025), $539000.0 (Q3 2025), and $511000.0 (Q2 2025).